SCHEMBL23326129

SCHEMBL23326129

COc1cc(C(F)(F)F)c(OC)cc1C1CCCN(C)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 10/20 1.00
HTR2C P28335 2/20 0.60
HTR2B P41595 2/20 0.60
HTR1A P08908 1/20 0.60
HTR1D P28221 1/20 0.60
HTR1E P28566 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
HTR7 P34969 1/20 0.60
HTR6 P50406 1/20 0.60
UTS2R Q9UKP6 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326127 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL23326224 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL29775391 1.00 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL29775396 0.85 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL29775428 0.85 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL23326125 0.85 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL23326270 0.85 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL23326126 0.85 HTR2A (1.00) HTR2AHTR2CHTR2BHTR1AHTR1D
SCHEMBL26473311 0.81 HTR2A (0.67) HTR2AHTR2C
SCHEMBL26473316 0.81 HTR2A (0.67) HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114761083-B 5-HT for treating depression 2A Agonists 罗福拉公司 2024-02-13 CN disclosed
EP-3962601-B1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2023-05-31 EP disclosed
EP-3962601-B1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2023-05-31 EP disclosed
US-11642336-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-05-09 US disclosed
US-11633390-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2023-04-25 US disclosed
CN-114761083-A 5-HT for the treatment of depression2AAgonists 罗福拉公司 2022-07-15 CN disclosed
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2022-03-03 US disclosed
US-11246860-B2 5-HT2A agonists for use in treatment of depression Lophora ApS (DK) 2022-02-15 US disclosed
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-10-28 US disclosed
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION Lophora ApS (DK) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210330658-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885
US-20220062257-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885
US-11642336-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885
US-20210137908-A1 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885
US-11633390-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885
US-11246860-B2 5-HT2A agonists for use in treatment of depression HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.